<!doctype html>

<!--[if lt IE 7]><html class="no-js ie6 oldie" lang="en"><![endif]-->
<!--[if IE 7]><html class="no-js ie7 oldie" lang="en"><![endif]-->
<!--[if IE 8]><html class="no-js ie8 oldie" lang="en"><![endif]-->
<!--[if gt IE 8]><!--><html class="no-js" lang="en"><!--<![endif]-->

<head>

	<!-- page specific -->

	<title>Written Authority Required Drugs 012-63060000</title>

	<!-- /page specific -->

	<meta charset="utf-8" />
	<meta http-equiv="X-UA-Compatible" content="IE=edge" />

	<meta name="DC.Coverage.jurisdiction" content="All" />
	<meta name="DC.Creator" content="Services Australia" />
	<meta name="DC.Format" scheme="IMT" content="text/html" />
	<meta name="DC.Language" scheme="RFC3066" content="en_AU" />
	<meta name="DC.Publisher" content="c=AU;o=Commonwealth of Australia;ou=Services Australia" />

	<meta name="format-detection" content="telephone=no" />

	<meta name="googlebot" content="noindex, nofollow" />
	<meta name="msnbot" content="noindex, nofollow" />
	<meta name="Slurp" content="noindex, nofollow" />

	<!-- mobile -->
	<meta name="HandheldFriendly" content="True" /> 
	<meta name="MobileOptimized" content="320" />
	<meta name="viewport" content="width=device-width, initial-scale=1.0" />
	<!-- /mobile -->

		function gtag(){dataLayer.push(arguments);}
		gtag('js', new Date());
		gtag('config', 'UA-145332323-3');

		// GA4 implementation
		(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
		new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
		j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
		'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
		})(window,document,'script','dataLayer','GTM-P42JWN8');
	</script>

	<!-- For all browsers -->
	<link rel="stylesheet" href="../../supportingContent/css/styles.css" media="screen" />
	<link rel="stylesheet" href="../../supportingContent/css/print.css" media="print" />

	<script type="text/javascript" src="../../supportingContent/js/jquery.min.js"></script>
	<script type="text/javascript" src="../../supportingContent/js/application.js"></script>

	<!--[if lt IE 9]>
		<script type="text/javascript" src="../../supportingContent/js/html5shiv.js"></script>
		<script type="text/javascript" src="../../supportingContent/js/html5shiv-printshiv.js"></script>
	<![endif]-->

	<!--[if lt IE 9]>
		<script type="text/javascript" src="../../supportingContent/js/respond.js"></script>
		<link rel="stylesheet" href="../../supportingContent/css/ie.css" />
	<![endif]-->

<title> 012-63060000</title></head>
<script>
$(document).ready(function() {
    var uUrl = location.href;
    if(uUrl.indexOf('-02.html') !== -1) {
        $("img").css('max-width','100%')
    }
});
</script>

<body class="operational operational-home no-gutters">

<div class="accessibility-hidden">
	<a href="#navigation">Skip to navigation</a>
	<a href="#content">Skip to content</a>
</div>

<!-- Begin Header section -->
<div id="header">
	<div id="header-top">
		<div class="container">
			<div class="row">
				<div class="ninecol last">
					<div id="agency-nav">
						<ul class="clearfix">
							<li class="humanservices-gov-au"><a href="http://www.servicesaustralia.gov.au/">servicesaustralia.gov.au</a></li>
						</ul>
					</div>
				</div>
			</div>
		</div>
	</div>
	<div class="container">
		<div class="row">
			<div class="threecol">
				<a title="Services Australia" id="crest-middle" href="http://www.servicesaustralia.gov.au/">
					<img alt="Services Australia website" id="screen-crest" src="../../supportingContent/images/New-Logo.png"/>
				</a>
			</div>

			<div class="ninecol last">
				<div class="global-nav-home clearfix" id="global-nav">
					<img alt="Services Australia website" id="mobile-crest" src="../../supportingContent/images/New-Logo-Mobile.png"/>
					<img alt="Services Australia website" id="brand-logo" src="../../supportingContent/images/SA-Logo.png"/>

					<div id="global-nav-menu">
						<ul id="global-nav-links">
							<li class="first"><a href="../../home.html" shape="">Home</a></li>
							<li><a href="https://findus.servicesaustralia.gov.au/" shape="">Find us</a></li>
							<li class="last"><a href="http://www.servicesaustralia.gov.au/customer/contact-us/" shape="">Contact us</a></li>
						</ul>
						<div class="search">
							<form method="get" action="/public/search/search.html"><input type="text" title="Search" onblur="if(this.value=='')this.value='search'" onfocus="if(this.value=='search')this.value=''" value="search" name="zoom_query" id="zoom_query"/><button type="submit" title="Search"><span>Search</span></button><input name='zoom_per_page' type="hidden" value="10" /></form>
						</div>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>
<!-- End Header section --> 
<!-- start pageData -->
<div class="container">
	<div class="row content-area">
		<div class="threecol">
			<!-- start pageDataNavLinks -->
			<div class="navigation clearfix" id="navigation">
				<ul>
					<li><a href="http://www.servicesaustralia.gov.au"> servicesaustralia.gov.au</a></li>
					<li><a href="../SiteMap/siteMap.html"> Site Map</a></li>
					<hr>
					<li><a href="../SiteMap/additional-products-and-services.html"> Additional products and services</a></li>
					<li><a href="../SiteMap/australians-overseas.html"> Australians overseas</a></li>
					<li><a href="../SiteMap/bereavement.html"> Bereavement</a></li>
					<li><a href="../SiteMap/business-and-employers.html"> Business and employers</a></li>
					<li><a href="../SiteMap/carers.html"> Carers</a></li>
					<li><a href="../SiteMap/ongoing-contact.html"> Change of circumstances</a></li>
					<li><a href="../SiteMap/compensation.html"> Compensation</a></li>
					<li><a href="../SiteMap/complaints-privacy-and-foi.html"> Complaints, privacy and Freedom of Information</a></li>
					<li><a href="../SiteMap/compliance-and-reviews.html"> Compliance & review</a></li>
					<li><a href="../SiteMap/debts.html"> Debts</a></li>
					<li><a href="../SiteMap/families.html"> Families</a></li>
					<li><a href="../SiteMap/health-professionals.html"> Health professionals</a></li>
					<li><a href="../SiteMap/help-in-an-emergency.html"> Help in an emergency</a></li>
					<li><a href="../SiteMap/income-assests-and-rates-of-payment.html"> Income, assets and rates of payment</a></li>
					<li><a href="../SiteMap/indigenous-australians.html"> Indigenous Australians</a></li>
					<li><a href="../SiteMap/initial-contact-general.html"> Initial contact & POI</a></li>
					<li><a href="../SiteMap/job-seekers.html"> Job seekers</a></li>
					<li><a href="../SiteMap/migrants-refugees-and-visitors.html"> Migrants, refugees & visitors</a></li>
					<li><a href="../SiteMap/older-australians.html"> Older Australians</a></li>
					<li><a href="../SiteMap/payment-delivery.html"> Payment delivery</a></li>
					<li><a href="../SiteMap/people-with-disability.html"> People with disability</a></li>
					<li><a href="../SiteMap/rural-and-remote-australians.html"> Remote & rural Australians</a></li>
					<li><a href="../SiteMap/review-of-decision-and-appeals.html"> Review of decision & appeals</a></li>
					<li><a href="../SiteMap/self-service.html"> Self service</a></li>
					<li><a href="../SiteMap/separated-parents.html"> Separated parents</a></li>
					<li><a href="../SiteMap/specialist-manuals-and-system-tools.html"> Specialist manuals & system tools</a></li>
					<li><a href="../SiteMap/students-and-trainees.html"> Students and trainees</a></li>
					<li><a href="../SiteMap/your-health.html"> Your health</a></li>
				</ul>
			</div>
			<!-- end pageDataNavLinks -->
		</div>

		<div class="ninecol last">
			<div id="content">
				<!--  The actual page data now fits in here  -->

				<!-- start pageDataHeading -->
				<h1>Written Authority Required Drugs 012-63060000</h1>
<ul id="tabs-primary"><li><a href="../health-professionals/012-63060000-01.html">Background</a></li><li><a href="../health-professionals/012-63060000-03.html">Process</a></li><li><a class="active students" href="../health-professionals/012-63060000-05.html">Resources</a></li></ul>
				<!-- end pageDataHeading -->

				<!-- start pageDataContent -->
				<div id="bgtab" class="">
					
<div id="relatedMessagesDiv"></div>


					<div class="unitRight"><a href="javascript:expandCollapseSections()" id="toggleText" alt="Expand/Collapse all sections" title="Expand/Collapse all sections"><img src="../../supportingContent/images/icons/toggle_plus.gif"align="top" id="toggleImage"border="0" alt="Expand/Collapse all sections"width="16" height="16">Expand all</a></div><br><br>

					<body>
<a name="top" class="anchor"></a><div id="contentObp" class="main"><div id="topnav"></div>


<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_Contact_details"></a>
<h2 id="bp05_L2GT_Contact_details">Contact details</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Pharmaceutical Benefits Scheme (PBS) - Complex Drugs Programs</p>
		</div>
	</div>
</div>


<p></p>
<div class="twisty">
	

<h2 id="Services Australia website">Services Australia website</h2>

	<div class="collapsible_container">
		<div class="block">

<p><a target="_blank" class="extwebsitelink" href="https&#58;//www.servicesaustralia.gov.au/health-professionals/services/medicare/complex-authority-required-drugs">Written Authority Required Drugs</a></p>
		</div>
	</div>
</div>


<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_abatacept_Oren"></a>
<h2 id="bp05_L2GT_abatacept_Oren">abatacept (OrenciaÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Abatacept is a Section 85 and Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required (Section 100 only).</p>

<p>Providing the patient meets specific restriction criteria, abatacept is subsidised for the treatment of&#58; </p>
		<ul>		<li>
rheumatoid arthritis</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_adalimumab_Hum"></a>
<h2 id="bp05_L2GT_adalimumab_Hum">adalimumab (HumiraÂ®/AmgevitaÂ®/HadlimaÂ®/HyrimozÂ®/IdacioÂ®/YuflymaÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Adalimumab is a Section 85 and Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required (Section 100 only).</p>

<p>Providing the patient meets specific restriction criteria, adalimumab is subsidised for the treatment of&#58;</p>
		<ul>		<li>
ankylosing spondylitis</li>
		<li>
Crohn's disease</li>
			<ul>			<li>
adult</li>
			<li>
paediatric</li>		</ul>
		<li>
fistulising Crohn's disease</li>
		<li>
hidradenitis suppurativa</li>
		<li>
juvenile idiopathic arthritis</li>
		<li>
psoriatic arthritis</li>
		<li>
rheumatoid arthritis</li>
		<li>
severe chronic plaque psoriasis</li>
			<ul>			<li>
adult</li>		</ul>
		<li>
ulcerative colitis</li>
			<ul>			<li>
adult</li>
			<li>
paediatric</li>
		</div>
	</div>
</div>
			</ul>			</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_aflibercept_Ey"></a>
<h2 id="bp05_L2GT_aflibercept_Ey">aflibercept (EyleaÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Aflibercept is a Section 85 listed pharmaceutical benefit. </p>

<p>Providing the patient meets specific restriction criteria, aflibercept is subsidised for the treatment of&#58;</p>
		<ul>		<li>
diabetic macular oedema </li>
		<li>
retinal vein occlusion with macular oedema</li>
		<li>
subfoveal choroidal neovascularisation due to&#58; </li>
			<ul>			<li>
age related macular degeneration</li>
			<li>
pathologic myopia</li>
			<li>
other causes</li>
		</div>
	</div>
</div>
			</ul>			</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_ambrisentan_Vo"></a>
<h2 id="bp05_L2GT_ambrisentan_Vo">ambrisentan (VolibrisÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Ambrisentan is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required.</p>

<p>Providing the patient meets specific restriction criteria, ambrisentan is subsidised for the treatment of&#58;</p>
		<ul>		<li>
pulmonary arterial hypertension</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_armodafinil_Nu"></a>
<h2 id="bp05_L2GT_armodafinil_Nu">armodafinil (NuvigilÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Armodafinil is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets the specific restriction criteria, armodafinil is subsidised for the treatment of&#58; </p>
		<ul>		<li>
narcolepsy</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_asciminib_Scem"></a>
<h2 id="bp05_L2GT_asciminib_Scem">asciminib (ScemblixÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Asciminib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets specific restriction criteria, asciminib is subsidised for the treatment of&#58;</p>
		<ul>		<li>
chronic myeloid leukaemia</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_avatrombopag_D"></a>
<h2 id="bp05_L2GT_avatrombopag_D">avatrombopag (DopteletÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Avatrombopag is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required.</p>

<p>Providing the patient meets specific restriction criteria, avatrombopag is subsidised for the treatment of&#58;</p>
		<ul>		<li>
idiopathic thrombocytopenic purpura</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_azacitidine_Vi"></a>
<h2 id="bp05_L2GT_azacitidine_Vi">azacitidine (VidazaÂ®/AzadineÂ®/CelazadineÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Azacitidine is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required.</p>

<p>Providing the patient meets specific restriction criteria, azacitidine is subsidised for the treatment of&#58;</p>
		<ul>		<li>
myelodysplastic syndrome</li>
		<li>
chronic myelomonocytic leukaemia</li>
		<li>
acute myeloid leukaemia</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_baricitinib_Ol"></a>
<h2 id="bp05_L2GT_baricitinib_Ol">baricitinib (OlumiantÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Baricitinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets specific restriction criteria, baricitinib is subsidised for the treatment of&#58;</p>
		<ul>		<li>
rheumatoid arthritis</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_benralizumab_F"></a>
<h2 id="bp05_L2GT_benralizumab_F">benralizumab (FasenraÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Benralizumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required.</p>

<p>Providing the patient meets specific restriction criteria, benralizumab is subsidised for the treatment of&#58;</p>
		<ul>		<li>
severe asthma</li>
			<ul>			<li>
adult</li>
			<li>
adolescent</li>
		</div>
	</div>
</div>
			</ul>			</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_bimekizumab_Bi"></a>
<h2 id="bp05_L2GT_bimekizumab_Bi">bimekizumab (BimzelxÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Bimekizumab is a Section 85 listed pharmaceutical benefit administered through PBS Complex Drugs team.</p>

<p>Providing the patient meets specific restriction criteria, bimekizumab is subsidised for the treatment of&#58;</p>
		<ul>		<li>
Severe chronic plaque psoriasis</li>
			<ul>			<li>
adult</li>
		</div>
	</div>
</div>
			</ul>			</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_blinatumomab_B"></a>
<h2 id="bp05_L2GT_blinatumomab_B">blinatumomab (BlincytoÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Blinatumomab is listed under Section 100 - Efficient funding of chemotherapy arrangements and is administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets specific restriction criteria, blinatumomab is subsidised for the treatment of&#58;</p>
		<ul>		<li>
acute lymphoblastic leukaemia</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_bosentan_monohy"></a>
<h2 id="bp05_L2GT_bosentan_monohy">bosentan monohydrate (TracleerÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Bosentan monohydrate is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required.</p>

<p>Providing the patient meets specific restriction criteria, bosentan monohydrate is subsidised for the treatment of&#58;</p>
		<ul>		<li>
pulmonary arterial hypertension</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_brentuximab_ved"></a>
<h2 id="bp05_L2GT_brentuximab_ved">brentuximab vedotin (AdcetrisÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Brentuximab vedotin is listed under Section 100 - Efficient funding of chemotherapy arrangements and is administered through the PBS Complex Drugs team. </p>

<p>Providing the patient meets the specific restriction criteria, brentuximab is subsidised for the treatment of&#58;</p>
		<ul>		<li>
CD30 positive systemic anaplastic large cell lymphoma</li>
		<li>
relapsed or refractory Hodgkin lymphoma</li>
		<li>
cutaneous T-cell lymphoma</li>
		<li>
peripheral T-cell lymphoma</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_brolucizumab_B"></a>
<h2 id="bp05_L2GT_brolucizumab_B">brolucizumab (BeovuÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>brolucizumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets the specific restriction criteria, brolucizumab is subsidised for the treatment of&#58;</p>
		<ul>		<li>
age related macular degeneration (AMD)</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_burosumab_Crys"></a>
<h2 id="bp05_L2GT_burosumab_Crys">burosumab (CrysvitaÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>burosumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required.</p>

<p>Providing the patient meets the specific restriction criteria, burosumab is subsidised for the treatment of&#58;</p>
		<ul>		<li>
X-linked hypophosphataemia (XLH)</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_certolizumab_pe"></a>
<h2 id="bp05_L2GT_certolizumab_pe">certolizumab pegol (CimziaÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Certolizumab pegol is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets the specific restriction criteria, certolizumab is subsidised for the treatment of&#58;</p>
		<ul>		<li>
rheumatoid arthritis</li>
		<li>
ankylosing spondylitis</li>
		<li>
psoriatic arthritis</li>
		<li>
non-radiographic axial spondyloarthritis</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_crizotinib_Xal"></a>
<h2 id="bp05_L2GT_crizotinib_Xal">crizotinib (XalkoriÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Crizotinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets specific restriction criteria, crizotinib is subsidised for the treatment of&#58;</p>
		<ul>		<li>
Stage IIIB or Stage IV non-small-cell lung cancer</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_dasatinib_Spry"></a>
<h2 id="bp05_L2GT_dasatinib_Spry">dasatinib (SprycelÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Dasatinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p> Providing the patient meets specific restriction criteria, dasatinib is subsidised for the treatment of&#58;</p>
		<ul>		<li>
acute lymphoblastic leukaemia </li>
		<li>
chronic myeloid leukaemia </li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_decitabineceda"></a>
<h2 id="bp05_L2GT_decitabineceda">decitabine+cedazuridine (InqoviÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Decitabine+cedazuridine is a Section 85 listed pharmaceutical benefit.</p>

<p>Providing the patient meets specific restriction criteria, decitabine+cedazuridine is subsidised for the treatment of&#58;</p>
		<ul>		<li>
acute myeloid leukaemia</li>
		<li>
chronic myelomonocytic leukaemia</li>
		<li>
myelodysplastic syndrome</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_dexamethasone_i"></a>
<h2 id="bp05_L2GT_dexamethasone_i">dexamethasone implant (OzurdexÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Dexamethasone is a Section 85 listed pharmaceutical benefit. </p>

<p>Providing the patient meets the specific restriction criteria, dexamethasone implant is subsidised for the treatment of&#58;</p>
		<ul>		<li>
diabetic macular oedema</li>
		<li>
retinal vein occlusion macular oedema</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_dupilumab_Dupi"></a>
<h2 id="bp05_L2GT_dupilumab_Dupi">dupilumab (DupixentÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Dupilumab is a Section 100 listed pharmaceutical benefit, and is administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required.</p>

<p>Providing the patient meets the specific restriction criteria, dupilumab is subsidised for the treatment of&#58;</p>
		<ul>		<li>
severe asthma</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_eculizumab_Sol"></a>
<h2 id="bp05_L2GT_eculizumab_Sol">eculizumab (SolirisÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Eculizumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required.</p>

<p>Providing the patient meets the specific restriction criteria, eculizumab is subsidised for the treatment of&#58;</p>
		<ul>		<li>
atypical haemolytic uraemic syndrome</li>
		<li>
paroxysmal nocturnal haemoglobinuria</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_elexacaftortez"></a>
<h2 id="bp05_L2GT_elexacaftortez">elexacaftor+tezacaftor+ivacaftor (TrikaftaÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Elexacaftor+tezacaftor+ivacaftor is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required.</p>

<p>Providing the patient meets the specific restriction criteria, elexacaftor+tezacaftor+ivacaftor is subsidised for the treatment of&#58;</p>
		<ul>		<li>
cystic fibrosis</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_elotuzumab_Emp"></a>
<h2 id="bp05_L2GT_elotuzumab_Emp">elotuzumab (EmplicitiÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Elotuzumab is listed under Section 100 - Efficient funding of chemotherapy arrangements and is administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets the specific restriction criteria, elotuzumab is subsidised for the treatment of&#58;</p>
		<ul>		<li>
multiple myeloma</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_eltrombopag_Re"></a>
<h2 id="bp05_L2GT_eltrombopag_Re">eltrombopag (RevoladeÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Eltrombopag is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required.</p>

<p>Providing the patient meets specific restriction criteria, eltrombopag is subsidised for the treatment of&#58;</p>
		<ul>		<li>
idiopathic thrombocytopenic purpura </li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_entrectinib_Ro"></a>
<h2 id="bp05_L2GT_entrectinib_Ro">entrectinib (RozlytrekÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Entrectinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets specific restriction criteria, entrectinib is subsidised for the treatment of&#58;</p>
		<ul>		<li>
Stage IIIB or Stage IV non-small-cell lung cancer </li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_epoprostenol_so"></a>
<h2 id="bp05_L2GT_epoprostenol_so">epoprostenol sodium (FlolanÂ®/VeletriÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Epoprostenol sodium is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required.</p>

<p>Providing the patient meets specific restriction criteria, epoprostenol sodium is subsidised for the treatment of&#58;</p>
		<ul>		<li>
pulmonary arterial hypertension</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_etanercept_Enb"></a>
<h2 id="bp05_L2GT_etanercept_Enb">etanercept (EnbrelÂ®/BrenzysÂ®) </h2>

	<div class="collapsible_container">
		<div class="block">

<p>Etanercept is a Section 85 and Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required (Section 100 only).</p>

<p>Providing the patient meets specific restriction criteria, etanercept is subsidised for the treatment of&#58;</p>
		<ul>		<li>
ankylosing spondylitis</li>
		<li>
juvenile idiopathic arthritis</li>
		<li>
psoriatic arthritis</li>
		<li>
rheumatoid arthritis</li>
		<li>
severe chronic plaque psoriasis </li>
			<ul>			<li>
adults</li>
			<li>
paediatric</li>
		</div>
	</div>
</div>
			</ul>			</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_faricimab_Vaby"></a>
<h2 id="bp05_L2GT_faricimab_Vaby">faricimab (Vabysmo)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Faricimab is a Section 85 listed pharmaceutical benefit.</p>

<p>Providing the patient meets specific restriction criteria, faricimab is subsidised for the treatment of&#58;</p>
		<ul>		<li>
diabetic macular oedema</li>
		<li>
subfoveal choroidal neovascularisation due to age related macular degeneration</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_golimumab_Simp"></a>
<h2 id="bp05_L2GT_golimumab_Simp">golimumab (SimponiÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Golimumab is a Section 85 listed pharmaceutical benefit administered through PBS Complex Drugs team.</p>

<p>Providing the patient meets specific restriction criteria, golimumab is subsidised for the treatment of&#58;</p>
		<ul>		<li>
ankylosing spondylitis</li>
		<li>
ulcerative colitis</li>
			<ul>			<li>
adult</li>		</ul>
		<li>
psoriatic arthritis</li>
		<li>
rheumatoid arthritis</li>
		<li>
non-radiographic axial spondyloarthritis</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_guselkumab_Tre"></a>
<h2 id="bp05_L2GT_guselkumab_Tre">guselkumab (TremfyaÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>guselkumab is a Section 85 listed pharmaceutical benefit administered through PBS Complex Drugs team.</p>

<p>Providing the patient meets specific restriction criteria, guselkumab is subsidised for the treatment of&#58;</p>
		<ul>		<li>
Psoriatic arthritis</li>
		<li>
Severe chronic plaque psoriasis</li>
			<ul>			<li>
adult</li>
		</div>
	</div>
</div>
			</ul>			</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_iloprost_tromet"></a>
<h2 id="bp05_L2GT_iloprost_tromet">iloprost trometamol (VentavisÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Iloprost trometamol is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required.</p>

<p>Providing the patient meets specific restriction criteria, iloprost trometamol is subsidised for the treatment of&#58;</p>
		<ul>		<li>
pulmonary arterial hypertension </li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_imatinib_Glive"></a>
<h2 id="bp05_L2GT_imatinib_Glive">imatinib (GlivecÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Imatinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets specific restriction criteria, imatinib is an agent subsidised for the treatment of&#58;</p>
		<ul>		<li>
chronic myeloid leukaemia </li>
		<li>
gastrointestinal stromal tumour</li>
		<li>
acute lymphoblastic leukaemia</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_infliximab_Rem"></a>
<h2 id="bp05_L2GT_infliximab_Rem">infliximab (RemicadeÂ®/InflectraÂ®/RenflexisÂ®/RemsimaÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Infliximab is a Section 85 and Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required (Section 100 only).</p>

<p>Providing the patient meets specific restriction criteria, infliximab is subsidised for the treatment of&#58;</p>
		<ul>		<li>
ankylosing spondylitis</li>
		<li>
Crohn's disease</li>
			<ul>			<li>
adults</li>
			<li>
paediatric (Section 100 only)</li>		</ul>
		<li>
fistulising Crohn's disease</li>
		<li>
psoriatic arthritis</li>
		<li>
rheumatoid arthritis</li>
		<li>
severe chronic plaque psoriasis </li>
			<ul>			<li>
adults</li>		</ul>
		<li>
ulcerative colitis</li>
			<ul>			<li>
adult</li>
			<li>
paediatric (Section 100 only)</li>
		</div>
	</div>
</div>
			</ul>			</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_ivacaftor_Kaly"></a>
<h2 id="bp05_L2GT_ivacaftor_Kaly">ivacaftor (KalydecoÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Ivacaftor is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required.</p>

<p>Providing the patient meets the specific restriction criteria, ivacaftor is subsidised for the treatment of&#58;</p>
		<ul>		<li>
cystic fibrosis</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_ixekizumab_Tal"></a>
<h2 id="bp05_L2GT_ixekizumab_Tal">ixekizumab (TaltzÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Ixekizumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets the specific restriction criteria, ixekizumab is subsidised for the treatment of&#58;</p>
		<ul>		<li>
ankylosing spondylitis</li>
		<li>
psoriatic arthritis</li>
		<li>
severe chronic plaque psoriasis</li>
			<ul>			<li>
adult</li>
		</div>
	</div>
</div>
			</ul>			</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_lanadelumab_Ta"></a>
<h2 id="bp05_L2GT_lanadelumab_Ta">lanadelumab (TakhzyroÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Lanadelumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets specific restriction criteria, lanadelumab is subsidised for the treatment of&#58;</p>
		<ul>		<li>
hereditary angioedema type 1 or 2</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_lapatinib_Tyke"></a>
<h2 id="bp05_L2GT_lapatinib_Tyke">lapatinib (TykerbÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Lapatinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets specific restriction criteria, lapatinib is subsidised for the treatment of&#58;</p>
		<ul>		<li>
metastatic breast cancer</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_larotrectinib_"></a>
<h2 id="bp05_L2GT_larotrectinib_">larotrectinib (VitrakviÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Larotrectinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets specific restriction criteria, larotrectinib is subsidised for the treatment of&#58;</p>
		<ul>		<li>
solid tumours that are confirmed to be neurotrophic tropomyosin receptor kinase (NTRK) gene fusion positive</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_lenalidomide_R"></a>
<h2 id="bp05_L2GT_lenalidomide_R">lenalidomide (RevlimidÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Lenalidomide is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required.</p>

<p>Providing the patient meets specific restriction criteria, lenalidomide is subsidised for the treatment of&#58;</p>
		<ul>		<li>
multiple myeloma</li>
		<li>
myelodysplastic syndrome</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_lumacaftorivac"></a>
<h2 id="bp05_L2GT_lumacaftorivac">lumacaftor+ivacaftor (OrkambiÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Lumacaftor+Ivacaftor is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required.</p>

<p>Providing the patient meets the specific restriction criteria, lumacaftor+ivacaftor is subsidised for the treatment of&#58;</p>
		<ul>		<li>
cystic fibrosis</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_macitentan_Ops"></a>
<h2 id="bp05_L2GT_macitentan_Ops">macitentan (OpsumitÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Macitentan is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required.</p>

<p>Providing the patient meets specific restriction criteria, macitentan is subsidised for the treatment of&#58;</p>
		<ul>		<li>
pulmonary arterial hypertension</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_mecasermin_Inc"></a>
<h2 id="bp05_L2GT_mecasermin_Inc">mecasermin (IncrelexÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Mecasermin is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets specific restriction criteria, mecasermin is subsidised for the treatment of&#58;</p>
		<ul>		<li>
Severe growth failure with primary insulin-like growth factor-1 deficiency</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_mepolizumab_Nu"></a>
<h2 id="bp05_L2GT_mepolizumab_Nu">mepolizumab (NucalaÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Mepolizumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required.</p>

<p>Providing the patient meets specific restriction criteria, mepolizumab is subsidised for the treatment of&#58;</p>
		<ul>		<li>
severe asthma</li>
			<ul>			<li>
adult</li>
			<li>
adolescent</li>		</ul>
		<li>
chronic rhinosinusitis with nasal polyps (CRSwNP)</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_midostaurin_Ry"></a>
<h2 id="bp05_L2GT_midostaurin_Ry">midostaurin (RydaptÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Midostaurin is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required.</p>

<p>Providing the patient meets specific restriction criteria, midostaurin is subsidised for the treatment of&#58;</p>
		<ul>		<li>
acute myeloid leukaemia</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_modafinil_Moda"></a>
<h2 id="bp05_L2GT_modafinil_Moda">modafinil (ModavigilÂ®/ModafinÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Modafinil is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets specific restriction criteria, modafinil is subsidised for the treatment of&#58;</p>
		<ul>		<li>
narcolepsy</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_nilotinib_Tasi"></a>
<h2 id="bp05_L2GT_nilotinib_Tasi">nilotinib (TasignaÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Nilotinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets specific restriction criteria, nilotinib is subsidised for the treatment of&#58;</p>
		<ul>		<li>
chronic myeloid leukaemia</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_nintedanib_Ofe"></a>
<h2 id="bp05_L2GT_nintedanib_Ofe">nintedanib (OfevÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Nintedanib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets specific restriction criteria, nintedanib is subsidised for the treatment of&#58;</p>
		<ul>		<li>
idiopathic pulmonary fibrosis</li>
		<li>
progressive fibrosing interstitial lung disease</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_nusinersen_Spi"></a>
<h2 id="bp05_L2GT_nusinersen_Spi">nusinersen (SpinrazaÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Nusinersen is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required.</p>

<p>Providing the patient meets specific restriction criteria, nusinersen is subsidised for the treatment of&#58;</p>
		<ul>		<li>
spinal muscular atrophy </li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_omalizumab_Xol"></a>
<h2 id="bp05_L2GT_omalizumab_Xol">omalizumab (XolairÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Omalizumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required.</p>

<p>Providing the patient meets specific restriction criteria, omalizumab is subsidised for the treatment of&#58;</p>
		<ul>		<li>
severe asthma</li>
		<li>
chronic spontaneous urticaria</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_onasemnogene_ab"></a>
<h2 id="bp05_L2GT_onasemnogene_ab">onasemnogene abeparvovec (ZolgensmaÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Onasemnogene abeparvovec is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public hospital authority required.</p>

<p>Providing the patient meets specific restriction criteria, onasemnogene abeparvovec is subsidised for the treatment of&#58;</p>
		<ul>		<li>
spinal muscular atrophy</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_ozanimod_Zepos"></a>
<h2 id="bp05_L2GT_ozanimod_Zepos">ozanimod (ZeposiaÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Ozanimod is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets specific restriction criteria, ozanimod is subsidised for the treatment of&#58;</p>
		<ul>		<li>
ulcerative colitis (adult)</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_pasireotide_Si"></a>
<h2 id="bp05_L2GT_pasireotide_Si">pasireotide (Signifor LARÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Pasireotide is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority is required.</p>

<p>Providing the patient meets specific restriction criteria, pasireotide is subsidised for the treatment of&#58;</p>
		<ul>		<li>
acromegaly</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_pegcetacoplan_"></a>
<h2 id="bp05_L2GT_pegcetacoplan_">pegcetacoplan (EmpaveliÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Pegcetacoplan is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required.</p>

<p>Providing the patient meets specific restriction criteria, pegcetacoplan is subsidised for the treatment of&#58;</p>
		<ul>		<li>
paroxysmal nocturnal haemoglobinuria</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_pegvisomant_So"></a>
<h2 id="bp05_L2GT_pegvisomant_So">pegvisomant (SomavertÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Pegvisomant is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority is required.</p>

<p>Providing the patient meets specific restriction criteria, pegvisomant is subsidised for the treatment of&#58;</p>
		<ul>		<li>
acromegaly</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_pertuzumab_Per"></a>
<h2 id="bp05_L2GT_pertuzumab_Per">pertuzumab (PerjetaÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Pertuzumab is listed under Section 100 - Efficient funding of chemotherapy arrangements and is administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets specific restriction criteria, pertuzumab is subsidised for the treatment of&#58;</p>
		<ul>		<li>
metastatic breast cancer</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_pirfenidone_Es"></a>
<h2 id="bp05_L2GT_pirfenidone_Es">pirfenidone (EsbrietÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Pirfenidone is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets specific restriction criteria, pirfenidone is subsidised for the treatment of&#58;</p>
		<ul>		<li>
idiopathic pulmonary fibrosis</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_polylactic_acid"></a>
<h2 id="bp05_L2GT_polylactic_acid">polylactic acid (SculptraÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Pirfenidone is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets specific restriction criteria, polylactic acid is subsidised for the treatment of&#58;</p>
		<ul>		<li>
severe facial lipoatrophy</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_pomalidomide_P"></a>
<h2 id="bp05_L2GT_pomalidomide_P">pomalidomide (PomalystÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Pomalidomide is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required.</p>

<p>Providing the patient meets specific restriction criteria, pomalidomide is subsidised for the treatment of&#58;</p>
		<ul>		<li>
multiple myeloma</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_ponatinib_Iclu"></a>
<h2 id="bp05_L2GT_ponatinib_Iclu">ponatinib (IclusigÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Ponatinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets specific restriction criteria, ponatinib is an agent subsidised for the treatment of&#58;</p>
		<ul>		<li>
chronic myeloid leukaemia </li>
		<li>
acute lymphoblastic leukaemia </li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_ranibizumab_Lu"></a>
<h2 id="bp05_L2GT_ranibizumab_Lu">ranibizumab (LucentisÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Ranibizumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team. </p>

<p>Providing the patient meets specific restriction criteria, ranibizumab is subsidised for the treatment of&#58;</p>
		<ul>		<li>
diabetic macular oedema </li>
		<li>
retinal vein occlusion with macular oedema</li>
		<li>
subfoveal choroidal neovascularisation due to&#58;</li>
			<ul>			<li>
age related macular degeneration </li>
			<li>
pathologic myopia </li>
			<li>
other causes </li>
		</div>
	</div>
</div>
			</ul>			</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_ravulizumab_Ul"></a>
<h2 id="bp05_L2GT_ravulizumab_Ul">ravulizumab (UltomirisÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Ravulizumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required.</p>

<p>Providing the patient meets specific restriction criteria, ravulizumab is subsidised for the treatment of&#58;</p>
		<ul>		<li>
paroxysmal nocturnal haemoglobinuria</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_riociguat_Adem"></a>
<h2 id="bp05_L2GT_riociguat_Adem">riociguat (AdempasÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Riociguat is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required.</p>

<p>Providing the patient meets specific restriction criteria, riociguat is subsidised for the treatment of&#58;</p>
		<ul>		<li>
pulmonary arterial hypertension </li>
		<li>
chronic thromboembolic pulmonary hypertension</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_ripretinib_Qin"></a>
<h2 id="bp05_L2GT_ripretinib_Qin">ripretinib (QinlockÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Ripretinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets specific restriction criteria, ripretinib is subsidised for the treatment of&#58;</p>
		<ul>		<li>
gastrointestinal stromal tumour</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_risankizumab_S"></a>
<h2 id="bp05_L2GT_risankizumab_S">risankizumab (SkyriziÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Risankizumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets specific restriction criteria, risankizumab is subsidised for the treatment of&#58;</p>
		<ul>		<li>
severe chronic plaque psoriasis </li>
			<ul>			<li>
adult</li>
		</div>
	</div>
</div>
			</ul>			</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_risdiplam_Evry"></a>
<h2 id="bp05_L2GT_risdiplam_Evry">risdiplam (EvrysidiÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Risdiplam is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required.</p>

<p>Providing the patient meets specific restriction criteria, risdiplam is subsidised for the treatment of&#58;</p>
		<ul>		<li>
spinal muscular atrophy</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_romiplostim_Np"></a>
<h2 id="bp05_L2GT_romiplostim_Np">romiplostim (NplateÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Romiplostim is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required.</p>

<p>Providing the patient meets specific restriction criteria, romiplostim is subsidised for the treatment of&#58;</p>
		<ul>		<li>
idiopathic thrombocytopenic purpura</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_ruxolitinib_Ja"></a>
<h2 id="bp05_L2GT_ruxolitinib_Ja">ruxolitinib (JakaviÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Ruxolitinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets specific restriction criteria, ruxolitinib is subsidised for the treatment of&#58; </p>
		<ul>		<li>
myelofibrosis </li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_secukinumab_Co"></a>
<h2 id="bp05_L2GT_secukinumab_Co">secukinumab (CosentyxÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Secukinumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets specific restriction criteria, secukinumab is subsidised for the treatment of&#58;</p>
		<ul>		<li>
ankylosing spondylitis</li>
		<li>
severe chronic plaque psoriasis</li>
			<ul>			<li>
adult</li>		</ul>
		<li>
psoriatic arthritis</li>
		<li>
non-radiographic axial spondyloarthritis</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_selinexor_Xpov"></a>
<h2 id="bp05_L2GT_selinexor_Xpov">selinexor (XpovioÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Selinexor is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required.</p>

<p>Providing the patient meets specific restriction criteria, selinexor is subsidised for the treatment of&#58;</p>
		<ul>		<li>
multiple myeloma</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_sildenafil_citr"></a>
<h2 id="bp05_L2GT_sildenafil_citr">sildenafil citrate (RevatioÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Sildenafil citrate is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required.</p>

<p>Providing the patient meets specific restriction criteria, sildenafil citrate is subsidised for the treatment of&#58; </p>
		<ul>		<li>
pulmonary arterial hypertension</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_somatrogon_Nge"></a>
<h2 id="bp05_L2GT_somatrogon_Nge">somatrogon (NgenlaÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Somatrogon is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets specific restriction criteria, somatrogon is subsidised for the treatment of&#58;</p>
		<ul>		<li>
growth hormone deficiency (paediatric)</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_somatropin_Gen"></a>
<h2 id="bp05_L2GT_somatropin_Gen">somatropin (GenotropinÂ®/NorditropinÂ®/NutropinÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Somatropin is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets specific restriction criteria, somatropin is subsidised for the treatment of </p>
		<ul>		<li>
growth hormone deficiency</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_sonidegib_Odom"></a>
<h2 id="bp05_L2GT_sonidegib_Odom">sonidegib (OdomzoÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Sonidegib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets specific restriction criteria, sonidegib is subsidised for the treatment of&#58;</p>
		<ul>		<li>
basal cell carcinoma</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_sunitinib_malat"></a>
<h2 id="bp05_L2GT_sunitinib_malat">sunitinib malate (SutentÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Sunitinib malate is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets specific restriction criteria, sunitinib malate is subsidised for the treatment of&#58; </p>
		<ul>		<li>
malignant gastrointestinal stromal tumour</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_tadalafil_Adci"></a>
<h2 id="bp05_L2GT_tadalafil_Adci">tadalafil (AdcircaÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Tadalafil is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required.</p>

<p>Providing the patient meets specific restriction criteria, tadalafil is used to treat patients with&#58;</p>
		<ul>		<li>
pulmonary arterial hypertension</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_teduglutide_Re"></a>
<h2 id="bp05_L2GT_teduglutide_Re">teduglutide (RevestiveÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Teduglutide is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required.</p>

<p>Providing the patient meets specific restriction criteria, teduglutide is subsidised for the treatment of&#58;</p>
		<ul>		<li>
short bowel syndrome with intestinal failure</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_tezacaftorivac"></a>
<h2 id="bp05_L2GT_tezacaftorivac">tezacaftor+ivacaftor (SymdekoÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Tezacaftor+Ivacaftor is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required.</p>

<p>Providing the patient meets the specific restriction criteria, tezacaftor+ivacaftor is subsidised for the treatment of&#58;</p>
		<ul>		<li>
cystic fibrosis</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_tildrakizumab_"></a>
<h2 id="bp05_L2GT_tildrakizumab_">tildrakizumab (IlumyaÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Tildrakizumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets specific restriction criteria, tildrakizumab is subsidised for the treatment of&#58;</p>
		<ul>		<li>
severe chronic plaque psoriasis</li>
			<ul>			<li>
adult</li>
		</div>
	</div>
</div>
			</ul>			</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_tocilizumab_Ac"></a>
<h2 id="bp05_L2GT_tocilizumab_Ac">tocilizumab (ActemraÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Tocilizumab is a Section 85 and Section 100 listed pharmaceutical benefit administered through PBS Complex Drugs team.</p>

<p>Public and private hospital authority required (section 100 listing only).</p>

<p>Providing the patient meets specific restriction criteria, tocilizumab is subsidised for the treatment of&#58;</p>
		<ul>		<li>
rheumatoid arthritis</li>
		<li>
systemic juvenile idiopathic arthritis</li>
		<li>
juvenile idiopathic arthritis</li>
		<li>
giant cell arteritis</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_tofacitinib_Xe"></a>
<h2 id="bp05_L2GT_tofacitinib_Xe">tofacitinib (XeljanzÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Tofacitinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets specific restriction criteria, tofacitinib is subsidised for the treatment of&#58; </p>
		<ul>		<li>
ankylosing spondylitis</li>
		<li>
psoriatic arthritis </li>
		<li>
rheumatoid arthritis</li>
		<li>
ulcerative colitis </li>
			<ul>			<li>
adult</li>
		</div>
	</div>
</div>
			</ul>			</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_trastuzumab_emt"></a>
<h2 id="bp05_L2GT_trastuzumab_emt">trastuzumab emtansine (KadcylaÂ®/HerceptinÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Trastuzumab emtansine is listed under Section 100 - Efficient funding of chemotherapy arrangements and is administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets specific restriction criteria, trastuzumab emtansine is subsidised for the treatment of&#58;</p>
		<ul>		<li>
metastatic breast cancer </li>
		<li>
early human epidermal growth factor receptor 2 positive breast cancer</li>
		<li>
gastric cancer </li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_upadacitinib_R"></a>
<h2 id="bp05_L2GT_upadacitinib_R">upadacitinib (RinvoqÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Upadacitinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets specific restriction criteria, upadacitinib is subsidised for the treatment of&#58;</p>
		<ul>		<li>
ankylosing spondylitis</li>
		<li>
non-radiographic axial spondyloarthritis</li>
		<li>
psoriatic arthritis</li>
		<li>
rheumatoid arthritis</li>
		<li>
ulcerative colitis </li>
			<ul>			<li>
adult</li>
		</div>
	</div>
</div>
			</ul>			</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_ustekinumab_St"></a>
<h2 id="bp05_L2GT_ustekinumab_St">ustekinumab (StelaraÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Ustekinumab is a Section 85 and Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required (Section 100 only).</p>

<p>Providing the patient meets specific restriction criteria, ustekinumab is subsidised for the treatment of&#58;</p>
		<ul>		<li>
severe chronic plaque psoriasis </li>
		<li>
psoriatic arthritis</li>
		<li>
Crohn's disease </li>
			<ul>			<li>
adult</li>		</ul>
		<li>
ulcerative colitis</li>
			<ul>			<li>
adult</li>
		</div>
	</div>
</div>
			</ul>			</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_vedolizumab_En"></a>
<h2 id="bp05_L2GT_vedolizumab_En">vedolizumab (EntyvioÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Vedolizumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Public and private hospital authority required.</p>

<p>Providing the patient meets specific restriction criteria, vedolizumab is subsidised for the treatment of&#58;</p>
		<ul>		<li>
crohn's disease</li>
			<ul>			<li>
adult</li>		</ul>
		<li>
ulcerative colitis</li>
			<ul>			<li>
adult</li>
		</div>
	</div>
</div>
			</ul>			</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_vismodegib_Eri"></a>
<h2 id="bp05_L2GT_vismodegib_Eri">vismodegib (ErivedgeÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Vismodegib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets specific restriction criteria, vismodegib is subsidised for the treatment of&#58;</p>
		<ul>		<li>
basal cell carcinoma</li>
		</div>
	</div>
</div>
		</ul>

<p></p>
<div class="twisty">
	
<a class="anchor" name="bp05_L2GT_vorinostat_Zol"></a>
<h2 id="bp05_L2GT_vorinostat_Zol">vorinostat (ZolinzaÂ®)</h2>

	<div class="collapsible_container">
		<div class="block">

<p>Vorinostat is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.</p>

<p>Providing the patient meets specific restriction criteria, vorinostat is subsidised for the treatment of&#58;</p>
		<ul>		<li>
cutaneous T-cell lymphoma</li>
		</div>
	</div>
</div>
		</ul>

<p></p>

<p></p>

<p></p>

<p></p>

<p></p></div><div class="rightpanel">
   
</div>

				</div>
				<!-- end primary tab container -->

				<!-- end pageDataContent -->
			</div>
		</div>
	</div>
</div>
<!-- end pageData -->

<!-- start footer -->
<div id="footer">
	<div id="bottom-stripe">
		<div class="container">
			<div class="row colour-stripe">
				<span class="le-1 first">&nbsp;</span>
				<span class="le-2">&nbsp;</span>
				<span class="le-3">&nbsp;</span>
				<span class="le-4">&nbsp;</span>
				<span class="le-5">&nbsp;</span>
				<span class="le-6">&nbsp;</span>
				<span class="le-7">&nbsp;</span>
				<span class="le-8">&nbsp;</span>
				<span class="le-9">&nbsp;</span>
				<span class="le-10">&nbsp;</span>
				<span class="le-11">&nbsp;</span>
				<span class="le-12">&nbsp;</span>
				<span class="le-13">&nbsp;</span>
				<span class="le-14">&nbsp;</span>
				<span class="le-15">&nbsp;</span>
				<span class="le-16">&nbsp;</span>
				<span class="le-17">&nbsp;</span>
				<span class="le-18 last">&nbsp;</span>
			</div>
		</div>
	</div>
	<div class="container">
		<div class="row" id="sub-footer">
			<ul>
				<li>Services Australia <acronym title="Australian Business Number">ABN</acronym> 90&nbsp;794&nbsp;605&nbsp;008&nbsp;</li>
			</ul>
		</div>
	</div>
</div>
<!-- end footer -->

<!-- start urchinTracker -->
<script type="text/javascript" src="../../supportingContent/js/urchin.js"></script>
<script type="text/javascript">if (typeof window.error404 === "undefined") { urchinTracker(); }</script>
<!-- end urchinTracker -->

</body>
</html>